Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Upgrading Dendreon To Buy (DNDN, $6.55)

Introduction
Over the last few months, I have been speaking to physicians and researchers who are using and studying Provenge. Based…
Read more…

Antares Initiated As A Buy (AIS, $2.59)

Investment Opinion
I am recommending purchase of Antares (AIS) at the current level of $2.59. My 2015 price target is $6.70.…
Read more…

Transcept Investment Thesis

Transcept just released a press release on July 12, 2011 with disappointing news on Intermezzo. The release reads as follows:

“Transcept…
Read more…

Orexigen Therapeutics (OREX)

The FDA has shown great reluctance to approve three anti-obesity agents under development: Orexigen’s Contrave, Vivus Qnexa and Arena’s Lorques.…
Read more…